Silihan lan utang jangka dawa perusahaan Clearside (CLSD)

Clearside Biomedical (CLSD) revenues are based on licensing payments for the use of the patented XIPERE device, with the figure standing at 0.00. The company is developing a comprehensive therapy system where the SCS Microinjector platform ensures high-precision drug delivery for retinal edema. This price action chart is supplemented by data on the robotization of assembly lines, which minimizes manual labor in the production of microinjectors.

CLSD Clearside Biomedical: Utang jangka dawa perusahaan ing interval 04.07.2022 - 13.12.2025

Rincian metrik keuangan lan pasar Clearside (CLSD)

- rega lan prakiraan konsensus rega:

Rega saham clearsidebio.com|CLSD - Bagan rega target

- data kapitalisasi pasar:

Nilai pasar Clearside Biomedical|CLSD - Nilai Total Perusahaan

- data kapitalisasi buku:

Nilai Akuntansi saben Saham Clearside Biomedical|CLSD - Kapitalisasi Buku|Rasio Kapitalisasi Pasar marang Nilai Buku clearsidebio.com|CLSD - Gunggung Aset Perusahaan

- data utang lan likuiditas:

Rasio Kabeh Utang marang Dana Pribadi Clearside Biomedical|CLSD - Utang jangka dawa marang modal|Kewajiban jangka cendhak marang modal Clearside Corp|CLSD - Gunggung utang perusahaan|Utang-utang marang nilai buku Clearside Biomedical|CLSD - Utang jangka dawa perusahaan|Utang jangka cendhak Clearside Biomedical

Pambiji fundamental:CLSD (clearsidebio.com)

Clearside Biomedical (CLSD) is developing innovative ophthalmological drugs amidst fierce competition and a heavy reliance on clinical trial results. This metric measures the total volume of long-term liabilities, enabling an assessment of capital structure stability and default risk via GURU.Markets tools by analyzing the company's current level of long-term debt as an indicator of the biopharmaceutical business's financial autonomy.

Pesaing langsung